Boehringer Ingelheim and BioMed X collaborate to discover new epigenetic regulators of COPD
BioMed X will be responsible for recruitment of the new research group, the operation of the innovation center facility, providing entrepreneurial education and enabling access to the Heidelberg scientific community and research facilities. "We welcome Boehringer Ingelheim as additional pharmaceutical partner to our Innovation Center", said Christian Tidona, founder and Managing Director of BioMed X. "This is a major milestone in our endeavor to bridge the translational gap between academia and the pharmaceutical industry."
Further details of the agreement and financial terms are not disclosed.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.